INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo LANSOLOC OTC (Capsules)
SCHEDULING STATUS:
S2

PROPRIETARY NAME
(and dosage form):

LANSOLOC OTC (Capsules)

COMPOSITION:
Each LANSOLOC OTC capsule contains lansoprazole 15 mg.

PHARMACOLOGICAL CLASSIFICATION:
A. 11.4.3 Medicines acting on the gastrointestinal tract.

PHARMACOLOGICAL ACTION:
Lansoprazole is an inhibitor of the gastric H+, K+-ATPase (proton pump).
Lansoprazole inhibits gastric acid secretion in a dose related manner irrespective of the source of stimulation. Gastric secretory functions recover gradually following discontinuation of the medicine.
Lansoprazole has no effect on histamine, gastrin or cholinergic receptors.
Pharmacokinetics:
Following oral administration, lansoprazole is well absorbed with a resultant bioavailability of approximately 78%. The bioavailability is decreased if lansoprazole is taken with food. Peak serum concentrations are achieved approximately 1-2 hours following ingestion.
Lansoprazole is highly protein bound (97%).
Lansoprazole is extensively metabolised via the hepatic cytochrome P450 system to the inactive, sulfated metabolites, sulphone, sulphide and 5-hydroxylansoprazole. The half-life for lansoprazole is 1,4 to 1,5 hours.
The main route of elimination is via the bile with 15-30% of lansoprazole being excreted via the kidneys as the hydroxylated metabolite.

INDICATIONS:
LANSOLOC OTC is indicated for the short-term symptomatic relief of heartburn and hyperacidity at a maximum daily dose of 15 mg for a maximum period of 14 days.

CONTRA-INDICATIONS:
• Hypersensitivity to lansoprazole or to any of the other ingredients.
• Pregnancy and lactation.
• Liver impairment.

WARNINGS:
Safety and efficacy in children has not been established.
Treatment with LANSOLOC OTC may alleviate the symptoms of malignant ulcers and can delay diagnosis. Therefore, the possibility of malignancy of a gastric ulcer or a malignant disease of the oesophagus should be excluded prior to treatment with LANSOLOC OTC.
This medicine may lead to drowsiness and impaired concentration that may be aggravated by the simultaneous intake of alcohol or other central nervous system depressants. Patients should be advised, particularly at the initiation of therapy, against taking charge of vehicles or machinery or performing potentially hazardous tasks where loss of concentration could lead to accidents.

INTERACTIONS:
• Since LANSOLOC OTC is a weak inducer of the cytochrome P450 system, the possibility exists for interactions with drugs which are metabolised via this system.
• Monitoring of patients receiving concomitant warfarin is recommended, since a minor reduction in the concentration of warfarin may occur.

PREGNANCY AND LACTATION:
Adequate and well-controlled studies in humans have not been done.
It is not known whether lansoprazole is distributed into breast milk.
However, lansoprazole or its metabolites are distributed into the milk of rats. Because lansoprazole has been shown to cause tumorigenic effects in animals, a decision should be made as to whether nursing should be discontinued or the medication withdrawn, taking into account the importance of lansoprazole to the mother.

DOSAGE AND DIRECTIONS FOR USE:
LANSOLOC OTC should preferably be taken before a meal.
Heartburn and hyperacidity:
One LANSOLOC OTC capsule (15 mg) daily for up to 14 days.
Patients should be advised to consult their doctor in the event of symptoms persisting, getting worse or continuing for 14 days
Elderly: No dose adjustment is necessary.
Renal impairment: No dose adjustment is necessary in renal failure.
This also applies to patients on dialysis.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Side-effects:
Cardiovascular disorders:
Less frequent: Oedema.
Neurological disorders:
Less frequent: Dizziness, headache, insomnia, somnolence, tremor.
Gastrointestinal disorders:
Frequent: Diarrhoea, nausea, vomiting, constipation, abdominal pain.
Less frequent: Dry mouth, glossitis, taste abnormalities, ulcerative colitis.
Endocrine disorders:
Less frequent: Gynaecomastia, galactorrhoea.
Hepatobiliary disorders:
Less frequent: Elevation in hepatic enzymes.
Musculoskeletal disorders:
Less frequent: Asthenia, arthralgia, myalgia.
Visual disorders:
Less frequent: Blurred vision.
Skin and subcutaneous tissue disorders:
Frequent: Rash, pruritus, urticaria.
Less frequent: Alopecia.
General disorders:
Less frequent: Fever.

Special Precautions:
It is important to confirm the diagnosis of reflux oesophagitis by endoscopy.

Effects related to acid inhibition:
During long-term treatment, gastric glandular cysts have been reported in increased frequency. These physiological changes result from pronounced inhibition of gastric acid secretion.
Decreased gastric acidity increases gastric counts of bacteria normally present in the gastro-intestinal tract. Treatment with LANSOLOC OTC may lead to an increased risk of gastro-intestinal infections such as Salmonella and Campylobacter.
In the presence of symptoms such as, significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena, and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with LANSOLOC OTC may alleviate symptoms and delay diagnosis.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
(See “SIDE-EFFECTS AND SPECIAL PRECAUTIONS”)
Treatment is symptomatic and supportive.

IDENTIFICATION:
LANSOLOC OTC: White to off-white, enteric coated pellets in hard gelatine capsule shells, size ‘3’, with blue cap and white body.

PRESENTATION:
LANSOLOC OTC: Blister-packed capsules in packs of 7 and 14.

STORAGE INSTRUCTIONS:
Store in a cool, dry place, below 25°C.
Protect from light.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
37/11.4.3/0238

NAME AND BUSINESS ADDRESS OF THE HOLDER OF THE CERTIFICATE OF REGISTRATION:
CIPLA LIFE SCIENCES (PTY) LTD
Rosen Heights, Pasita Street,
Rosen Park, BELLVILLE 7530

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
July 2005

© CIPLA LIFE SCIENCES (PTY) LTD

New addition to this site: January 2007
Source: Community Pharmacy

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2007